Skip to content
lifestyle.celebhomes.net
Home
Sample Page
Author:
Edgewise Therapeutics
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
June 1, 2026
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up
March 10, 2026
Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026
February 8, 2026
Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026
January 13, 2026
Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
January 6, 2026
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
December 2, 2025
Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors
November 26, 2025